for people ages 18-75 (full criteria)
at San Francisco, California and other locations
study started
estimated completion
Principal Investigator
by Melvin Heyman
Photo of Melvin Heyman
Melvin Heyman



A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered Janus kinase 1 inhibitor, in adult participants with Crohn's Disease.

Official Title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Crohn's Disease Who Completed the Studies M14-431 or M14-433


Crohn's Disease Upadacitinib ABT-494 Extension Study Efficacy Safety Maintenance Study Crohn Disease


You can join if…

Open to people ages 18-75

For Substudy 1:

  • Participant who achieve clinical response in Study M14-431 or Study M14-433.
  • Participant completes study procedures in the parent study. The final endoscopy for Studies M14-431 or M14-433 may be missing, if the endoscopy cannot be performed during the COVID-19 pandemic.

For Substudy 2:

  • Participant completes Substudy 1. The Week 52 endoscopy may be missing, if the endoscopy cannot be performed during the COVID-19 pandemic.
  • Participant who achieved clincal response at the time descibed in the protocol and completes study procedures in the parent study/ substudy.

You CAN'T join if...

For Sub-studies 1 and 2:

  • Participant is considered by the investigator, for any reason, to be an unsuitable candidate for the study.
  • Participant who has a known hypersensitivity to upadacitinib or its excipients, or had an adverse event during Studies M14-431 and M14-433 or Substudy 1 of Study M14-430 that in the investigator's judgment makes the participant unsuitable for this study.
  • Participant with any active or chronic recurring infections based on the investigator's assessment that makes the participant an unsuitable candidate for the study. Participants with serious infections undergoing treatment may be enrolled BUT NOT dosed until the infection treatment has been completed and the infection is cured, based on the investigator's assessment.
  • Participants with high grade colonic dysplasia or malignancy diagnosed at the endoscopy performed at the final visit of Studies M14-431, M14-433 or Substudy 1 of Study M14-430 (Week 52).


  • UCSF Center for Colitis and Crohn's Disease /ID# 202372
    San Francisco California 94115-3011 United States
  • Univ of California San Francis /ID# 164653
    San Francisco California 94158 United States

Lead Scientist at UCSF

  • Melvin Heyman
    Professor, Pediatrics. Authored (or co-authored) 312 research publications.


accepting new patients by invitation only
Start Date
Completion Date
This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.
Phase 3
Study Type
Last Updated